Kura Oncology and Kyowa Kirin Report Phase 1/2 KOMET-007 Long-Term Survival Data Supporting Frontline AML Registration

Long-term efficacy data from the KOMET-007 trial are now shaping the CMC and regulatory planning horizon for Kura Oncology and Kyowa Kirin as their Phase 3 registrational study, KOMET-017, advances ziftomenib toward a potential frontline AML indication. Updated results, presented at the European Hematology Association 2026 Congress, show a 12-month overall survival rate of 94% in NPM1-mutated patients and 71% in KMT2A-rearranged patients treated with ziftomenib plus intensive 7+3 chemotherapy, outcomes that compare favorably to historical 7+3 benchmarks of approximately 70–80% OS in younger fit NPM1-m patients.

Composite complete remission rates reached 96% in NPM1-m AML and 90% in KMT2A-r AML across 49 patients dosed at 600 mg ziftomenib. Local CRc MRD-negativity rates were 85% and 82% respectively, with central marrow NGS testing at a 10⁻⁴ threshold corroborating local assay findings. Median OS was not reached in either molecular subgroup at median follow-up of 17.6 months (NPM1-m) and 11.0 months (KMT2A-r). Data cut-off was April 10, 2026.

For QA directors and regulatory affairs leads, the transition from a monotherapy approval to a combination-use pathway introduces distinct process validation and CMC considerations. KOMZIFTI (ziftomenib) currently holds FDA approval solely as monotherapy for relapsed or refractory NPM1-m AML with no satisfactory alternative; its use with 7+3 remains investigational. A combination NDA or sNDA would require updated drug-drug interaction characterisation, revised labelling, and potentially additional stability data reflecting co-administration conditions under 21 CFR Part 211 and ICH Q10 quality system expectations.

Manufacturing scale-up to support a frontline indication, a substantially larger eligible population than the R/R setting, will require validated commercial-scale processes ahead of any pre-approval inspection. Plant heads should note that the KOMET-017 Phase 3 enrolment trajectory will set the timeline pressure on those readiness milestones. Lead investigator Amer Zeidan of Yale Cancer Center noted that depth of response in this disease can directly inform long-term treatment decisions, including the potential to reduce reliance on allogeneic hematopoietic cell transplantation, a clinical outcome that, if confirmed in Phase 3, would further broaden the commercial and manufacturing demand profile.

Kura is hosting a virtual investor event on June 12, 2026, where additional programme details are expected; regulatory and manufacturing teams tracking KOMET-017 timelines should monitor any updated enrolment or interim analysis disclosures that could accelerate submission planning.

The durability of composite remission and MRD-negativity rates across both molecular subtypes will be the measurable outcomes that ultimately anchor the KOMET-017 primary endpoint analysis and any subsequent regulatory submission package.

Source: Kura Oncology / Kyowa Kirin via GlobeNewswire, June 11, 2026. Virtual investor event: June 12, 2026, 8:00 a.m. ET.